US/UK/Canada

Share

Contacts

  • Orexo
    Box 303 751 05 Uppsala
    +46 (0)18 780 88 00
    +46 (0)18 780 88 88
    http://www.orexo.com

    • Quotes

    With the acquisition of the rights to two digital health products from GAIA and the appointment of Dennis, a thought leader in the digital health industry in the US, we are well positioned to lead this development within the complementary disease areas of our pharmaceutical business.
    Nikolaj Sørensen, President and CEO
    Our strategy is to focus on solutions with scientifically proven therapeutic effect which will benefit the healthcare system as a whole and more importantly patients.
    Nikolaj Sørensen, CEO, about Digital Therapies
    I am convinced that DTx will become an integral and natural part of addiction treatment in the future. This digital therapy for OUD patients is perfectly positioned with Orexo’s competences and commercial organization in the US.
    Nikolaj Sørensen, President and CEO
    Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for a successful launch of Zubsolv®
    Nikolaj Sørensen, President and CEO
    Pick a time period -
    Tags ( Active)

    Promising results from human PK study assessing novel ketorolac formulations for treatment of pain

    · OX338 demonstrated improved bioavailability and tolerability compared to commercially available reference product · Further work required to optimise product formulation Uppsala, Sweden – January 29, 2020. Orexo AB (publ.) today announces promising results from its OX338 pharmacokinetic study, evaluating novel formulations of ketorolac, a non-addictive, non-steroidal anti-inflammatory drug (NSAID) for the treatment of pain. Orexo’s OX338 formulations demonstrated improved bioavailability and tolerability compared to the commercially available reference product. In addition, one

    Abstral® launched and now available in the United States

    Uppsala, April 4, 2011 - Orexo AB (STO: ORX) announces today that its partner ProStrakan Group plc (LSE: PSK) has launched Abstral in the United States. Abstral, which is the only fast-acting sublingual tablet for the treatment of breakthrough cancer pain, is now available to patients in the US. In 2010 the market value for fast-acting fentanyl products was $530m. (Source: Wolter Kluwers).  Abstral was approved by the US Food and Drug Administration (FDA) in January 2011, and is the first product to be approved in the US with the FDA mandated class Risk Evaluation and Mitigation

    Orexo announces successful completion of the first clinical trial in OX51

    Uppsala, Sweden, March 31, 2011 - Orexo AB (STO: ORX) announces the positive outcome following completion of the initial pharmacokinetic trial in the OX51 project. The project is aimed at developing a sublingual dosage form tailored to treat acute intensive pain episodes in relation to care-related diagnostic or therapeutic procedures for patients whom are not receiving sufficient pain relief. Orexo plans to enter the next stage of development during the second half of 2011 following discussions with regulatory authorities. Orexo currently has 3 fully owned programs (including OX51)

    Orexo and Boehringer Ingelheim report progress in their pain and inflammatory diseases collaboration

    Uppsala/Sweden and Ingelheim/Germany, December 16, 2010 - Orexo AB (STO: ORX) and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in  October 2007. The aim of the collaboration is to develop a new class of medication with a novel mechanism of action for the treatment of pain and inflammatory diseases. The selection

    Orexo signs agreement for Abstral™ for the Middle East and Africa

    Uppsala, September 16, 2010 - Orexo AB (STO: ORX) announces today that an exclusive licensing and distribution agreement has been signed with NewBridge Pharmaceuticals for Abstral™, Orexo´s product for the treatment of breakthrough cancer pain. The agreement grants NewBridge rights to seek approval for Abstral™ in the Middle East and Africa and, where approval is granted, to market and sell the product in these territories. The agreement covers 64 countries across the Middle East and Africa, and excludes Israel where the product is already partnered. Under the terms of the agreement,

    Orexo announces that partner Kyowa Hakko Kirin is to conduct additional clinical trials on KW-2246 for treatment of cancer pain in Japan

    Uppsala, Sweden, August 27, 2010 – Orexo AB (STO: ORX) announces today that its partner Kyowa Hakko Kirin Co, Ltd. has decided to conduct additional clinical trials on the cancer pain drug KW-2246 (Orexo’s sublingual fentanyl product Abstral®). An application for production and sale in Japan of KW-2246 as a treatment for breakthrough pain in cancer patients was made on February 24, 2010. However, following consultation with the Pharmaceuticals and Medical Devices Agency during the screening process, it was decided that additional data was required to supplement the application documents.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media